Wuxi Apptec Co.Ltd(603259) (603259) released the performance express on February 15. The operating revenue in 2021 was 22.902 billion yuan, a year-on-year increase of 38.5%; The net profit attributable to the parent company was 5.097 billion yuan, a year-on-year increase of 72.19%. Among them, the chemical business realized an income of about RMB 14.087 billion in 2021, with a year-on-year increase of about 46.93%. It is noteworthy that the company expects the revenue growth of the chemical business sector in 2022 to nearly double that of 2021.
On February 15, Yaoming stocks all started the soaring mode: Wuxi Apptec Co.Ltd(603259) A shares closed at the limit, Wuxi Apptec Co.Ltd(603259) Hong Kong stocks rose 12.13%, and Yaoming biology in Hong Kong stocks rose 10.09%.
chemical business income in 2022
The growth rate of is expected to nearly double
In 2021, Wuxi Apptec Co.Ltd(603259) maintained strong growth. According to the performance express, the operating revenue in 2021 was 22.902 billion yuan, a year-on-year increase of 38.5%; The net profit attributable to the parent company was 5.097 billion yuan, a year-on-year increase of 72.19%; The basic earnings per share is 1.75 yuan.
Wuxi Apptec Co.Ltd(603259) said in the announcement that the company has always implemented the strategy of “following the molecules”. The integrated chemical business (Wuxi Chemistry) sector continues to build an “integrated, end-to-end” crdmo (contract research, development and production organization) business. The strong demand for orders has promoted the accelerated growth of the company’s annual sales revenue in 2021.
Specifically, the revenue of chemical business in 2021 was about 14.087 billion yuan, 9.588 billion yuan compared with the same period in 2020, a year-on-year increase of about 46.93%. Among them, the service revenue of small molecule drug discovery (R) increased by about 43.24% year-on-year; The service revenue of process R & D and production (D & M) increased by about 49.94% year-on-year. It is noteworthy that the company expects the revenue growth of the chemical business sector in 2022 to nearly double that of 2021.
The test business also implements
strong growth
The business growth of SMO / testing and Biology Laboratory (XO / testing) in 2021 was also strong. Specifically, the revenue of test business in 2021 was about 4.525 billion yuan, which was 3.278 billion yuan compared with the same period in 2020, with a year-on-year increase of about 38.03%. Among them, the revenue of laboratory analysis and testing services increased by about 38.93% year-on-year. If excluding drug analysis and testing services other than device testing, it increased strongly by about 52.12% year-on-year; The revenue of clinical cro and SMO increased by about 36.20% year-on-year. The company expects that the revenue growth of test business in 2022 will continue the momentum in recent years.
The biological business (Wuxi Biology) realized an income of about 1.985 billion yuan in 2021, which was 1.526 billion yuan compared with the same period in 2020, with a year-on-year increase of about 30.05%.
The ctdmo business of cell and gene therapy (Wuxi ATU) realized an income of about 1.026 billion yuan in 2021, which was 1.056 billion yuan compared with the same period in 2020, a year-on-year decrease of about 2.79%. The ctdmo business of cell and gene therapy in China grew rapidly, realizing a year-on-year increase of about 87%, which partially alleviated the impact of the decline in the business in the United States caused by the delay in the submission of listing applications by some customers. Wuxi Apptec Co.Ltd(603259) said that 2022 of cell and gene therapy ctdmo business segment (Wuxi ATU) will be a turning year for business development, and the company expects revenue growth to exceed the growth rate of the industry.
The revenue of China new drug research and Development Service Department (Wuxi ddsu) was about 1.251 billion yuan in 2021, which was 1.065 billion yuan compared with the same period in 2020, with a year-on-year increase of about 17.47%. The business of China new drug R & D Service Department (Wuxi ddsu) will be upgraded iteratively in 2022 to meet customers’ higher requirements for China’s new drug R & D services. The company expects the revenue to decline to a certain extent.
Yao Ming’s stock opened the soaring mode
Since July 2021, Wuxi Apptec Co.Ltd(603259) share price has fluctuated lower, with a cumulative decline of more than 40%. According to the data, the total market value of Wuxi Apptec Co.Ltd(603259) A shares is 273.1 billion yuan, second only to Shenzhen Mindray Bio-Medical Electronics Co.Ltd(300760) 386.8 billion yuan in the pharmaceutical sector and higher than Jiangsu Hengrui Medicine Co.Ltd(600276) 263.5 billion yuan. Among Jiangsu A-share listed companies, the total market value of Wuxi Apptec Co.Ltd(603259) is less than 260.6 billion yuan of Jiangsu Yanghe Brewery Joint-Stock Co.Ltd(002304) , also ranking second.
On February 8, it was reported that the US Department of Commerce included 33 Chinese entities in the “unverified list” (UVL), imposed new restrictions on these entities’ access to products from US exporters, and asked us companies wishing to do business with these Chinese companies to conduct additional investigations. The “unverified list” includes listed companies such as Hong Kong stock Yaoming biology.
Affected by the above news, YaoMing’s share price fell sharply on February 8. A shares Wuxi Apptec Co.Ltd(603259) opened sharply lower by more than 9% in the morning, then fell by the limit in seconds, the share price hit a new low in more than a year, and the market value evaporated by more than 30 billion yuan. The Wuxi Apptec Co.Ltd(603259) H shares plunged by more than 27% in the session, and the Hong Kong stock drug Ming biology fell by nearly 32% at most in the session.
At noon, A-share Wuxi Apptec Co.Ltd(603259) issued a Clarification Announcement, saying that neither the company nor its subsidiaries were included in the “unverified list” by the U.S. Department of Commerce, and the current production and operation conditions are normal. After the news was released, the decline of YaoMing system narrowed in the afternoon. Hong Kong stocks Wuxi Apptec Co.Ltd(603259) finally fell to 10.39%. A shares Wuxi Apptec Co.Ltd(603259) once opened the limit board, and Hong Kong stocks Yaoming biological was temporarily suspended, down 22.77%.
It is understood that at the Wuxi Apptec Co.Ltd(603259) online communication meeting, when asked about the recent listing of two subsidiaries of YaoMing biology by the U.S. Department of Commerce, he stressed that Wuxi Apptec Co.Ltd(603259) business and operation are normal, Wuxi Apptec Co.Ltd(603259) is not on the UVL list and is not expected to be included in the list in the future. Wuxi Apptec Co.Ltd(603259) stressed at the exchange meeting: “all our certification documents are up-to-date, and our suppliers have always maintained good communication with government agencies on relevant approval. The company strictly abides by relevant laws and regulations of the United States, and welcomes the supervision of the U.S. Department of Commerce and other regulatory agencies, including on-site inspection as needed.”
On February 15, Yaoming stocks all started the soaring mode: Wuxi Apptec Co.Ltd(603259) A shares closed at the limit, Wuxi Apptec Co.Ltd(603259) Hong Kong stocks rose 12.13%, and Yaoming biology in Hong Kong stocks rose 10.09%.
